Market Landscape
What is the Burden of Asthma?
26 Million
People have asthma in the U.S.
U$56 Billion
Is spent in asthma related healthcare
4,000
People die from asthma-related conditions every year
15 Million
Workdays are lost due to asthma-related issues
50%
Of all people with asthma present high levels of eosinophils
14 Million
School days are lost due to asthma-related issues
1.3 Million
Emergency Room Visits
Currently, Most Eosinophil-Lowering Drugs for Asthma Are Monoclonal Antibodies that Must Be Injected or Infused in Regular Clinic Visits.
Knopp is Advancing Dexpramipexole, an Eosinophil-Lowering Oral Agent for Asthma
Find Out More About DexpramipexoleHypereosinophilic Syndrome
For some, eosinophils migrate into specific tissues, damaging organs through the release of toxic proteins and signaling molecules
The heart is frequently affected in HES, leading to ventricular damage and eventual cardiac failure
Other targets include the skin, nervous system, lungs, GI tract, liver, spleen and eyes
Currently, the standard of care for those with HES is corticosteroids, which may present significant side effects
Side effects of steroids may include hormone suppression, elevated blood sugar, loss of bone density, mood and behavioral disturbances.
1/3 of HES patients fail to respond to steroid administration.
Dexpramipexole is under investigation as a potential solution for those suffering with hypereosinophilic syndrome